Allurion Technologies (ALUR) Competitors $2.72 +0.01 (+0.18%) Closing price 06/11/2025 03:58 PM EasternExtended Trading$2.71 0.00 (-0.18%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALUR vs. INO, TELA, NSPR, MLSS, VANI, CTSO, EDAP, ZYXI, APYX, and HYPRShould you be buying Allurion Technologies stock or one of its competitors? The main competitors of Allurion Technologies include Inovio Pharmaceuticals (INO), TELA Bio (TELA), InspireMD (NSPR), Milestone Scientific (MLSS), Vivani Medical (VANI), Cytosorbents (CTSO), Edap Tms (EDAP), Zynex (ZYXI), Apyx Medical (APYX), and Hyperfine (HYPR). These companies are all part of the "medical equipment" industry. Allurion Technologies vs. Its Competitors Inovio Pharmaceuticals TELA Bio InspireMD Milestone Scientific Vivani Medical Cytosorbents Edap Tms Zynex Apyx Medical Hyperfine Allurion Technologies (NYSE:ALUR) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability. Which has more volatility & risk, ALUR or INO? Allurion Technologies has a beta of -0.47, indicating that its stock price is 147% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Do institutionals & insiders have more ownership in ALUR or INO? 21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 22.4% of Allurion Technologies shares are owned by company insiders. Comparatively, 2.3% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer ALUR or INO? Allurion Technologies presently has a consensus price target of $22.83, suggesting a potential upside of 741.01%. Inovio Pharmaceuticals has a consensus price target of $9.75, suggesting a potential upside of 359.91%. Given Allurion Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Allurion Technologies is more favorable than Inovio Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allurion Technologies 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Inovio Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community prefer ALUR or INO? Inovio Pharmaceuticals received 713 more outperform votes than Allurion Technologies when rated by MarketBeat users. Likewise, 70.69% of users gave Inovio Pharmaceuticals an outperform vote while only 66.67% of users gave Allurion Technologies an outperform vote. CompanyUnderperformOutperformAllurion TechnologiesOutperform Votes866.67% Underperform Votes433.33% Inovio PharmaceuticalsOutperform Votes72170.69% Underperform Votes29929.31% Does the media refer more to ALUR or INO? In the previous week, Inovio Pharmaceuticals had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 2 mentions for Inovio Pharmaceuticals and 1 mentions for Allurion Technologies. Inovio Pharmaceuticals' average media sentiment score of 1.73 beat Allurion Technologies' score of 1.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Allurion Technologies Positive Inovio Pharmaceuticals Very Positive Is ALUR or INO more profitable? Inovio Pharmaceuticals has a net margin of 0.00% compared to Allurion Technologies' net margin of -71.24%. Allurion Technologies' return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Allurion Technologies-71.24% N/A -56.75% Inovio Pharmaceuticals N/A -118.17%-83.47% Which has higher valuation & earnings, ALUR or INO? Allurion Technologies has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllurion Technologies$28.30M0.72-$80.61M-$12.50-0.22Inovio Pharmaceuticals$283.10K274.63-$135.12M-$3.19-0.66 SummaryAllurion Technologies and Inovio Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Get Allurion Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALUR vs. The Competition Export to ExcelMetricAllurion TechnologiesSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$20.25M$4.41B$5.57B$19.81BDividend YieldN/A42.67%5.28%3.84%P/E Ratio-0.2328.4427.1235.67Price / Sales0.7271.85412.3046.74Price / CashN/A51.0838.2517.52Price / Book-0.075.917.064.84Net Income-$80.61M$67.63M$3.23B$1.02B7 Day Performance-0.37%2.35%2.86%1.94%1 Month Performance14.08%17.24%9.07%3.03%1 Year Performance-92.19%19.59%31.45%9.73% Allurion Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALURAllurion Technologies2.8786 of 5 stars$2.72+0.2%$22.83+741.0%-91.2%$20.25M$28.30M-0.23501Positive NewsShort Interest ↓Gap DownINOInovio Pharmaceuticals4.0836 of 5 stars$2.22-2.2%$9.75+339.2%-78.2%$81.42M$283.10K-0.70320Positive NewsTELATELA Bio2.4547 of 5 stars$1.86-1.6%$7.25+289.8%-66.7%$73.57M$71.22M-1.10120NSPRInspireMD2.0482 of 5 stars$2.40-4.0%$4.50+87.5%-8.6%$73.52M$7.03M-3.2050MLSSMilestone Scientific2.3112 of 5 stars$0.91-0.5%$1.25+37.7%+22.1%$71.26M$8.61M-12.9730Short Interest ↑Gap UpVANIVivani Medical3.0001 of 5 stars$1.15flat$4.00+247.8%-27.0%$68.13MN/A-2.5620News CoveragePositive NewsCTSOCytosorbents1.9397 of 5 stars$1.08+1.9%$5.50+409.3%+21.2%$67.62M$35.33M-3.00220Positive NewsEDAPEdap Tms2.2802 of 5 stars$1.80+1.1%$8.50+372.2%-66.2%$67.31M$62.77M-2.77230Positive NewsZYXIZynex3.028 of 5 stars$2.19+0.5%$6.00+174.0%-78.0%$66.22M$172.40M14.60770Positive NewsAPYXApyx Medical2.9405 of 5 stars$1.73+3.6%N/A+14.3%$65.38M$47.29M-2.08270Short Interest ↓HYPRHyperfine3.3947 of 5 stars$0.77-2.8%$1.06+36.9%-7.0%$60.26M$11.73M-1.36190Positive NewsGap Up Related Companies and Tools Related Companies Inovio Pharmaceuticals Competitors TELA Bio Competitors InspireMD Competitors Milestone Scientific Competitors Vivani Medical Competitors Cytosorbents Competitors Edap Tms Competitors Zynex Competitors Apyx Medical Competitors Hyperfine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ALUR) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allurion Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allurion Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALUR Stock Free ALUR Stock Alerts